Amendment to Annual Report (Form 10-K/A)

This Amendment No. 1 to the Annual Report on Form 10-K of Ultralife Corporation (the "Company") for the year ended December 31, 2025 as originally filed with the Securities and Exchange Commission (the "SEC") on March 23, 2026 (the "Original Form 10-K"), is being filed solely to include the information required by Items 10, 11, 12, 13 and 14 of Part III and to amend Item 15 of Part IV and the Index of Exhibits of Original Form 10-K. This information required by Part III of Form 10-K was omitted from the Original Form 10-K in reliance on General Instruction G(3) to Form 10-K, which permits the information in the above referenced items to be incorporated in the Form 10-K by reference from our definitive proxy statement if such proxy statement is filed no later than 120 days after our fiscal year-end. We are including this Part III information in this Amendment No. 1 to the Original Form 10-K because we will not file a definitive proxy statement containing such information within 120 days after the end of the fiscal year covered by the Original Form 10-K. We plan on filing our definitive proxy statement on or about June 2, 2026 as we are holding our 2026 Annual Stockholders' Meeting (the "Meeting") on July 22, 2026.

In accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended ("the Exchange Act"), Part III, Items 10, 11, 12, 13 and 14, and Part IV, Item 15 of the Original Form 10-K are hereby amended and restated in their entirety. Accordingly, the reference on the cover page of the Original Form 10-K to the incorporation by reference of portions of our definitive proxy statement into Part III of the Original Form 10-K is hereby deleted. Pursuant to Rule 12b-15 and Rule 13a-14(a) under the Exchange Act, this Amendment No. 1 contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed as exhibits to this Amendment No. 1.

Except as expressly described above, this Amendment No. 1 does not amend, modify, or otherwise update any financial or other information in or on exhibits filed with the Original Form 10-K. Accordingly, this Amendment No.1 should be read in conjunction with the Original Form 10-K and our other filings with the SEC, including without limitation, the Company's consolidated financial statements and related disclosures in the Original Form 10-K, which remain unchanged. In addition, this Amendment No. 1 does not change any financial information in the Original Form 10-K or reflect events that may have occurred subsequent to the filing date of the Original Form 10-K.

Unless expressly indicated or the context requires otherwise, the terms "Company," "we," "our," and "us" in this document refer to Ultralife Corporation ("Ultralife"), a Delaware corporation, and, where appropriate, its subsidiaries.